Compare SCSC & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCSC | LTGO |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1997 | 2026 |
| Metric | SCSC | LTGO |
|---|---|---|
| Price | $61.70 | $16.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $60.50 | $52.25 |
| AVG Volume (30 Days) | 189.9K | ★ 240.1K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.33 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $3,846,260,000.00 | N/A |
| Revenue This Year | $10.38 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $33.76 | $16.19 |
| 52 Week High | $66.78 | $25.93 |
| Indicator | SCSC | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 34.69 |
| Support Level | $55.67 | $16.19 |
| Resistance Level | $59.23 | $20.49 |
| Average True Range (ATR) | 1.32 | 1.68 |
| MACD | -0.01 | -0.67 |
| Stochastic Oscillator | 82.56 | 7.32 |
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.